Notable
PHOENIX · QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Recruitment opened
Guangdong Association of Clinical TrialsPhase 2 NCT07416058 Registry history of NCT07416058 on ClinicalTrials.gov (opens the registry)